| (USD) | Jun 2022 | Q/Q |
|---|---|---|
| Revenue | 14.8MM | +6% |
| Gross Profit | 13.9MM | - |
| Cost Of Revenue | 963K | -1% |
| Operating Income | 5.2MM | +31% |
| Operating Expenses | 8.7MM | - |
| Net Income | 4.1MM | +21% |
| G&A | 3.4MM | +3% |
| Marketing | 4.2MM | -10% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of U.S. financial markets on Tuesday, May 7, 2024. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Renae Cormier, c
Every investor on earth makes bad calls sometimes. But you want to avoid the really big losses like the plague. So take...
With its stock down 37% over the past month, it is easy to disregard Semler Scientific (NASDAQ:SMLR). However, stock...
Revenue Climbs 20% and Net Income Soars 44% for the Year as Company Strengthens Market Position
Semler Scientific, Inc. (NASDAQ:SMLR) Q4 2023 Earnings Call Transcript March 5, 2024 Semler Scientific, Inc. misses on earnings expectations. Reported EPS is $0.55 EPS, expectations were $0.57. SMLR isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome […]
Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023.
Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023, after the close of U.S. financial markets on Tuesday, March 5, 2024. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same d
Conestoga Capital Advisors, an asset management company, released its “Micro Cap Strategy” fourth-quarter 2023 investor letter. A copy of the same can be downloaded here. Despite growing by 12.70% net of fees in the fourth quarter, the strategy was unable to match the 15.64% return of the Russell Micro Cap Growth Index. Underperformance was mostly caused […]
Semler Scientific, Inc. ( NASDAQ:SMLR ), might not be a large cap stock, but it saw a significant share price rise of...
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...